<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Familial hypercholesterolemia in adults: Overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Familial hypercholesterolemia in adults: Overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Familial hypercholesterolemia in adults: Overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Durrington, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2722172000"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Familial hypercholesterolemia (FH) is a common genetic disease caused by mutation of one or more of the genes critical for low-density lipoprotein cholesterol (LDL-C) catabolism (see <a class="local">'Genetic considerations'</a> below). [<a href="#rid1">1</a>] The clinical syndrome (phenotype) is characterized by extremely elevated levels of LDL-C and a propensity to early onset atherosclerotic cardiovascular disease. Homozygotes generally manifest disease in childhood. (See  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children"</a>.)</p><p>This topic will focus on issues not related to the primary goal of therapy, which is to significantly lower LDL-C levels. Treatment details are presented separately. (See  <a class="medical medical_review" href="/d/html/111815.html" rel="external">"Familial hypercholesterolemia in adults: Treatment"</a>.)</p><p>Other inherited lipid disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p class="headingAnchor" id="H4212208012"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>An individual may be labeled as having FH in one of two ways: </p><p class="bulletIndent1"><span class="glyph">●</span>DNA-based evidence of mutation in the <em>LDLR, PCSK9,</em> or <em>APOB</em> gene. Each of these genes influence LDL-C levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical characteristics that usually include a high LDL-C.</p><p></p><p>The following are three recognized diagnostic criteria schemes [<a href="#rid2">2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Dutch Lipid Clinic  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Simon Broome  (<a class="graphic graphic_table graphicRef111789" href="/d/graphic/111789.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>American Heart Association criteria for the clinical diagnosis of FH: low-density lipoprotein cholesterol (LDL-C) &gt;190 mg/dL (&gt;4.9 mmol/L) and either a first degree relative with LDL-C&gt;190 mg/dL or with known premature coronary heart disease (55 years men; &lt;60 years women) [<a href="#rid3">3</a>].</p><p></p><p>When possible, we will attempt to specify which definition is being used.</p><p class="headingAnchor" id="H384771452"><span class="h1">GENETIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>FH is the most common autosomal dominant genetic disease. Patients with FH usually have a functional mutation of one of three genes: the low-density lipoprotein receptor gene (<em>LDLR</em>; sometimes called the apoB/E receptor); gain-of-function mutations of the proprotein convertase subtilisin kexin 9 gene (<em>PCSK9</em>), and the apolipoprotein B gene (principally <em>APOB3500</em>)  (<a class="graphic graphic_table graphicRef117227" href="/d/graphic/117227.html" rel="external">table 3</a>). Each of these three mutations impairs LDL receptor-mediated catabolism of the LDL particle, leading to higher LDL-C in the blood [<a href="#rid4">4,5</a>]. Of these, <em>LDLR</em> mutations are by far the most common. Mutations in these genes exhibit additive gene dosing effects, such that individuals with two pathogenic mutations (homozygotes or compound heterozygotes) are more adversely affected than those with one pathogenic mutation (heterozygotes)  (<a class="graphic graphic_figure graphicRef105115" href="/d/graphic/105115.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. </p><p>The prevalence of pathogenic mutation in at least one of these three genes varies by the degree of certainty of FH definition, estimated at about 80 percent in patients with <strong>definite</strong> FH clinical syndrome and 20 to 30 percent of those with <strong>possible</strong> FH syndrome [<a href="#rid6">6-9</a>]. Among those with one of these three mutations, 85 to 90 percent have <em>LDLR </em>mutations, 2 to 4 percent gain-of function <em>PCSK9</em> mutations, and 1 to 12 percent <em>APOB</em> mutations [<a href="#rid10">10-14</a>]. </p><p>Those individuals who meet the phenotypic criteria for clinical FH (see <a class="local">'Definition'</a> above) and in whom no causative single gene mutation is identified (up to 20 percent in some series), are labeled as having severe polygenic hypercholesterolemia, whereby the combination of small effects of multiple individual variants jointly lead to a significantly elevated LDL-C [<a href="#rid6">6,13,15-17</a>]. Polygenic risk scores that estimate an individual's genetic risk by quantifying the burden of known susceptibility variants have been developed for hypercholesterolemia. The cumulative effect of multiple small effect loci can result in LDL-C levels within the same range as a single major gene associated with heterozygous FH [<a href="#rid18">18</a>]. In addition, some individuals with the highest polygenic risk scores (those above the 90th percentile of genetic risk) also carry additional deleterious monogenic variants [<a href="#rid6">6,8,17,19</a>]. Polygenic hypercholesterolemia is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Polygenic hypercholesterolemia'</a>.) </p><p>It is likely that only a very small proportion of patients with FH have some as of yet undiscovered causative single gene mutation. For example, mutations in a signal transducing adaptor family member 1 (<em>STAP1</em>), occurring in &lt;0.1 percent of cases, have been proposed as candidates to be the fourth cause of FH. </p><p class="headingAnchor" id="H2835787208"><span class="h2">Impact on clinical presentation</span><span class="headingEndMark"> — </span>The development of atherosclerotic cardiovascular disease (ASCVD) attributable to elevated LDL is more related to the duration and degree of LDL-C elevation than it is to the specific genetic defect(s) present. Adults with heterozygous (and homozygous) FH have had high levels of LDL-C since birth, whereas adults with high LDL-C levels not due to FH have had high LDL-C for a shorter duration of time and thus are at somewhat lower risk of premature ASCVD. </p><p>Due to the above described additive effects of pathogenic variation on LDL-C levels, patients with two pathogenic variants or one pathogenic variant and high polygenic cholesterol risk score can present with ASCVD early in life. Also, at similar levels of LDL-C as adults, the presence of monogenic FH increases the risk of premature CVD by about two- to fourfold relative to individuals without an FH-causing variant. This is consistent with observations that heterozygous FH patients typically have high LDL-C levels from birth and a higher risk of premature coronary heart disease. Genetic variations other than the three major ones described above (see <a class="local">'Genetic considerations'</a> above) cause more minor LDL-C raising and may also affect the LDL-C in FH patients and contribute to age at onset and severity of cardiovascular risk [<a href="#rid6">6,20</a>]. In general, heterozygous FH patients have high LDL-C levels from birth and a higher risk of premature coronary heart disease compared to polygenic individuals who usually do not have very high LDL-C levels in early life.</p><p>In adults, LDL-C concentrations should be treated similarly regardless of whether a definite diagnosis of FH has been made or whether the polygenic score is high [<a href="#rid5">5,19,21</a>]. However, the presence of a high <strong>polygenic</strong> risk score in a patient with monogenic FH is a very high risk. </p><p class="headingAnchor" id="H3551017297"><span class="h2">LDL receptor genetic defects</span><span class="headingEndMark"> — </span>In its most common form, FH is a monogenic disorder caused by defects in the gene that encodes for the apo B/E (LDL) receptor [<a href="#rid11">11,22-24</a>]. The associated impairment in function of these receptors results in reduced clearance of LDL particles from the circulation and an elevation in plasma LDL-C. In general, plasma levels of LDL-C are inversely related to the level of residual LDLR activity. There is also increased uptake of modified LDL (oxidized or other modifications) by the macrophage scavenger receptors, resulting in macrophage lipid accumulation and foam cell formation [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Lipoproteins and atherosclerosis'</a>.)</p><p>Over 1600 different mutations in the LDLR gene have been identified [<a href="#rid26">26</a>]. The mutations at the LDLR locus have been categorized into four classes of alleles based on the phenotypic behavior of the mutant protein [<a href="#rid22">22</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class I</strong> – Null, in which synthesis is defective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class II</strong> – Transport defective, in which intracellular transport from the endoplasmic reticulum to Golgi is impaired.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class III</strong> – Binding defective, in which proteins are synthesized and transported to the cell surface normally, but binding of LDL is defective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class IV</strong> – Internalization defective, in which proteins reach the cell surface and bind LDL normally but the receptors do not cluster in the coated pits, thereby minimizing LDL internalization.</p><p></p><p>Patients with FH may be classified into one of two major groups based on the amount of LDLR activity: patients with less than 2 percent (receptor-negative) and patients with 2 to 25 percent of normal LDLR activity (receptor-defective) [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H4257373371"><span class="h2">Mutations in the PCSK9 gene</span><span class="headingEndMark"> — </span>Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease that is secreted by the liver. Extracellularly, it binds the LDLR expressed principally on liver cells. Once the PCSK9-LDLR complex is internalized into the hepatocyte physiologically through the coated pit region of its outer membrane, LDL receptors bound to PCSK9 are prevented from recycling to the cell surface and undergo destruction inside liver cells [<a href="#rid28">28</a>]. Fewer LDL receptors lead to less clearance of LDL-C and higher serum levels. Gain-of-function mutations in PCSK9 are rare, but lead to decreased LDLR expression, decreased LDL catabolism, higher levels of LDL-C, the heterozygous FH clinical syndrome, and increased risk of ischemic heart disease; loss-of-function mutations are more common and are associated with reductions of both LDL-C and risk of ischemic heart disease.</p><p>The following observations summarize the clinical importance of PCSK9:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated PCSK9 levels are associated with reduced expression of the hepatic LDLR and increased serum LDL-C [<a href="#rid29">29,30</a>]. There are polymorphisms in the PCSK9 gene that are associated with increased severity of coronary atherosclerosis in patients with <strong>polygenic</strong> hypercholesterolemia [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Polygenic hypercholesterolemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In multiple population studies, carriers of the loss-of-function 46L allele of PCSK9 have lower levels (9 to 16 percent) of LDL-C as well as a lower risk (6 to 47 percent) of ischemic heart disease compared with noncarriers [<a href="#rid32">32,33</a>]. In a meta-analysis of three large population studies, 46L allele carriers had a 12 percent reduction in LDL-C and a 28 percent reduction in the risk of ischemic heart disease [<a href="#rid33">33</a>]. The observed reduction in LDL-C predicted only 5 percent of the reduction in the risk of ischemic heart disease. Explanations include a greater effect with lifelong exposure or other non-LDL-C-lowering effects. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statins increase serum levels of PCSK9 in a dose-dependent manner, potentially lessening their LDL-C-lowering effect, particularly with dose escalation [<a href="#rid34">34</a>]. In a case-control substudy of the TNT trial of high- versus low-dose statin therapy in patients with stable coronary heart disease, circulating PCSK9 levels measured at randomization were predictive of major cardiovascular events at five years in the group assigned to 10 mg of <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> but not in the group assigned to 80 mg [<a href="#rid35">35</a>]. At one year, there was no difference in PCSK9 levels between the two treatment groups nor was there any difference between randomization or one-year levels in either treatment arm. </p><p></p><p>Infusion of a monoclonal antibody to PCSK9 reduces LDL-C levels [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/106888.html" rel="external">"PCSK9 inhibitors: Pharmacology, adverse effects, and use", section on 'Clinical use'</a>.)</p><p class="headingAnchor" id="H4210656928"><span class="h2">Familial defective apolipoprotein B-100</span><span class="headingEndMark"> — </span>Familial defective apo B-100 is an autosomal dominant disorder that is associated with impaired binding of LDL particles to the apo B/E (LDL) receptor [<a href="#rid37">37</a>]. The defect is localized to the apo B-100 ligand on the LDL particle (mutation at residue 3500), not the apo B/E (LDL) receptor. The net effect is that the clearance of LDL is reduced and plasma levels increase by two- to threefold. The frequency of the apo B 3500 mutation among patients classified as FH heterozygotes is as high as 3 percent [<a href="#rid38">38,39</a>].</p><p>Only a minority of people inheriting of APOB3500 express raised LDL-C to the same extent as those inheriting loss of function LDLR mutations. One study evaluated the frequency and clinical significance of the apolipoprotein B 3500 mutation in 9255 subjects from the general population, 948 patients with coronary heart disease, and 36 patients with FH [<a href="#rid40">40</a>]. The mutation was present in 0.08 percent of subjects in the general population in whom the mean serum cholesterol concentration was 100 mg/dL (2.6 mmol/L) higher than in those without the mutation. The increment in serum cholesterol above the general population was more pronounced in the patients with coronary heart disease (154 mg/dL [4.0 mmol/L]) and those with FH (172 mg/dL [4.5 mmol/L]). Heterozygotes for the mutation were more common in patients with CHD (odds ratio 7.0) and FH (odds ratio 78) compared with the general population. </p><p class="headingAnchor" id="H1321616434"><span class="h1">VARIATION IN LDL-C</span><span class="headingEndMark"> — </span>While the low-density lipoprotein cholesterol (LDL-C) level is heavily dependent on one of the three genes discussed above (see <a class="local">'Genetic considerations'</a> above), other genes may further alter the LDL-C level  (<a class="graphic graphic_figure graphicRef112674" href="/d/graphic/112674.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p>The likelihood of a monogenic or an oligogenic cause for heterozygous FH becomes increasingly likely the higher the LDL-C [<a href="#rid19">19</a>]. (See <a class="local">'Genetic considerations'</a> above.)</p><p>In addition, other factors such as diet, comorbid diseases (eg, hypothyroidism, liver disease), or genetic abnormalities not related to the LDL receptor, PCSK9, or apolipoprotein B genes may alter LDL-C levels. In addition, acute viral illness or inflammatory state or the post-surgical state can have a transient suppression of lipid synthesis that typically lowers LDL-C. (See  <a class="medical medical_review" href="/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a>.)</p><p><strong>GENETIC TESTING</strong> — Several companies and academic medical centers offer panels of tests (LDL-R) that capture major pathogenic low-density lipoprotein receptor mutations, ApoB3500 mutations, and PCSK9 gain of function mutations. In most cases, we order a gene-sequencing test. There is no population screening for FH in the United States; however, an investigation suggested it may be cost effective to perform in United States adults younger than 40 years if the testing cost is relatively low and probands have access to preventive interventions [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H3570900191"><span class="h2">Indications</span><span class="headingEndMark"> — </span>There is no widespread agreement as to when genetic testing is indicated in the process of evaluating a very elevated LDL-C. In general, we order such tests only when the results might alter clinical decision making. </p><p>There are two possible reasons for genetic testing:</p><p class="bulletIndent1"><span class="glyph">●</span>When the diagnosis is unclear from the LDL-C concentration, usually this is around puberty when its habitual level decreases due to the growth spurt or when some other illness lowers LDL. This is not absolute; the cholesterol can be repeated at a later stage when it has returned to its more typical level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of tendon xanthomata in the proband is a good reason to begin cascade screening. The point of cascade is to identify affected relatives, usually younger ones who have yet to develop ASCVD. (See  <a class="medical medical_review" href="/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H1707449948"><span class="h2">Incidental finding</span><span class="headingEndMark"> — </span>Some patients will have genetic testing performed for reasons other than the two discussed directly above. Occasionally, a variant for FH is detected. In these patients, we evaluate the individual’s cardiovascular risk and consider intensive LDL-C lowering if a high lifetime risk is present.</p><p class="headingAnchor" id="H41183973"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>FH is the most common monogenic, autosomal dominant disorder in humans. The reported prevalence of FH will vary by the definition used (see <a class="local">'Definition'</a> above) and the population (impact of the gene pool) studied. The evidence suggests that the prevalence of heterozygous FH in the general (or nonconsanguineous) population worldwide is about 1 in 300 individuals [<a href="#rid2">2,4,20,42-46</a>]. Homozygous patients are rare and have an estimated prevalence of approximately 1:300,000 to 1:400,000 [<a href="#rid4">4</a>]. Prevalence in consanguineous populations is higher. </p><p>Two large meta-analyses were published in 2020 to establish the worldwide prevalence of heterozygous FH [<a href="#rid47">47,48</a>]. In one, more than seven million people [<a href="#rid47">47</a>] were involved, and in the other, nearly 11 million [<a href="#rid48">48</a>]. Typically, using the Dutch Lipid Clinic Network Criteria for the diagnosis  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 1</a>), the prevalence of heterozygous FH was similar in both reports: 1 in 311 and 1 in 31 of the general population, respectively. The prevalence among patients with atherosclerotic cardiovascular disease (ASCVD) [<a href="#rid47">47</a>] was 18 times higher, and in patients with premature IHD (as defined by the individual investigators), 21 times higher [<a href="#rid48">48</a>]. The findings in these two meta-analyses were consistent with earlier studies [<a href="#rid43">43,49-51</a>]. (See <a class="local">'Definition'</a> above and <a class="local">'Genetic considerations'</a> above.)</p><p>It should be kept in mind that the great majority of the estimated 7 percent of Americans with LDL-C exceeding 190 mg/dL do not fulfill the clinical criteria for a definite diagnosis of heterozygous FH and nor do they have any identifiable DNA mutation likely to cause heterozygous FH [<a href="#rid5">5</a>]. However, the combination of raised LDL-C and an identifiable FH-causing mutation significantly increases the risk for coronary artery disease above that of people with similar LDL-C but no FH-causing mutation. </p><p class="headingAnchor" id="H163827326"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients with undiagnosed <strong>homozygous</strong> familial hypercholesterolemia (FH) develop severe, premature, atherosclerotic cardiovascular disease and die before age 20 in many cases. (See  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children"</a>.)</p><p>In previously undiagnosed <strong>heterozygous</strong> FH, patients present with symptoms or signs of atherosclerotic cardiovascular disease (eg, angina, corneal arcus, xanthelasma, tendon xanthoma, or periosteal xanthoma) or adverse atherosclerotic cardiovascular disease events (eg, myocardial infarction, sudden cardiac death) in early middle age. In addition, many patients will be identified by the finding of a low-density lipoprotein cholesterol greater than the 90 percentile for age and sex when the test was performed for cardiovascular risk screening  (<a class="graphic graphic_figure graphicRef112674" href="/d/graphic/112674.html" rel="external">figure 2</a>). </p><p>Coronary artery calcification, a marker of coronary artery disease, can be identified at 11 to 23 years of age in heterozygotes [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a>.)</p><p>Patients demonstrate tendon xanthomata if untreated, and frequently have a family history of hypercholesterolemia  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 1</a>). Some of the excess LDL-C is deposited in the arteries as atheroma and in the tendons and skin as xanthomata  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083 graphicRef67239" href="/d/graphic/52572.html" rel="external">picture 1A-D</a>) and xanthelasma  (<a class="graphic graphic_picture graphicRef67919" href="/d/graphic/67919.html" rel="external">picture 2</a>). The prevalence of xanthomata increases with age, eventually occurring in 75 percent of FH heterozygotes. </p><p class="headingAnchor" id="H3438849135"><span class="h1">CLINICAL SUSPICION</span><span class="headingEndMark"> — </span>A diagnosis of familial hypercholesterolemia (FH) should be suspected in adults with any of the following [<a href="#rid43">43,53,54</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Elevated plasma low-density lipoprotein cholesterol (LDL-C) – The level of LDL-C that warrants further evaluation depends upon whether additional family members have known hypercholesterolemia and/or early cardiovascular disease. In patients with a negative or unknown family history, an untreated LDL-C level of ≥190 mg/dL (4.9 mmol/L) suggests FH. This value is greater than the 90<sup>th</sup> percentile for age and sex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family member with known FH or elevated cholesterol (total cholesterol &gt;240 mg/dL [6.2 mmol/L] in either parent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholesterol deposits (called xanthomas, which often occur in tendons, around the cornea, or perioral) in the patient or family members.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature coronary heart disease in the patient or family member(s). Among young patients with premature acute coronary syndromes in Switzerland (mean age about 50 years), 1.6 percent had probable/definite FH (Dutch Lipid Clinic definition) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sudden premature cardiac death in a family member. </p><p></p><p class="headingAnchor" id="H954981025"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>In patients suspected of familial hypercholesterolemia (FH) (see <a class="local">'Clinical suspicion'</a> above), the evaluation includes a complete history and physical examination and some laboratory tests. An evaluation for secondary causes of hypercholesterolemia  (<a class="graphic graphic_table graphicRef71294" href="/d/graphic/71294.html" rel="external">table 4</a>) should be performed. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Secondary causes of hypercholesterolemia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Personal history</strong> – The personal history should pay attention to symptoms or signs of ASCVD such as angina, transient ischemic attack, claudication or prior myocardial infarction, stroke, or arterial revascularization. The patient should be evaluated for the presence of other major risk factors for ASCVD. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Established risk factors for atherosclerotic CVD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history</strong> – A detailed family history is essential in establishing the diagnosis of FH. Identifying family members with premature coronary heart disease, tendon xanthomas, and elevated cholesterol levels (particularly if present during childhood) help support the diagnosis of FH. Caregivers should also obtain a history of thyroid, renal, hepatic, or biliary disease in order to exclude secondary causes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The physical examination is directed at identifying evidence of abnormal deposits of cholesterol in the skin and eyes, which are rarely seen in children except in those with homozygous FH and sitosterolemia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tendon xanthomata  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083" href="/d/graphic/52572.html" rel="external">picture 1A-C</a>) are most common in the Achilles tendons and dorsum of the hands, but can occur at other sites.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Planar xanthomas  (<a class="graphic graphic_picture graphicRef67239" href="/d/graphic/67239.html" rel="external">picture 1D</a>) may occur on the palms of the hands and soles of the feet and are often painful.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Xanthelasmas  (<a class="graphic graphic_picture graphicRef67919" href="/d/graphic/67919.html" rel="external">picture 2</a>) are cholesterol-filled, soft, yellow plaques that usually appear on the medial aspects of the eyelids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Corneal arcus is a white or grey ring around the cornea  (<a class="graphic graphic_picture graphicRef112680" href="/d/graphic/112680.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef112681" href="/d/graphic/112681.html" rel="external">picture 4</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The pulses of the major arteries should be checked looking for evidence of vascular obstruction</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of aortic stenosis should be sought. (See  <a class="medical medical_review" href="/d/html/8164.html" rel="external">"Clinical manifestations and diagnosis of aortic stenosis in adults", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fasting lipid profile</strong> – The characteristic fasting lipid profile in patients with FH consists of elevated total and low-density lipoprotein cholesterol with normal or low high-density lipoprotein cholesterol and normal triglyceride (TG) levels (unless the patient is obese, has diabetes, or other mutations in triglyceride-regulating genes, in which case TG levels may also be elevated). Elevated TG levels do not exclude the diagnosis of FH; however, other potential causes of hypertriglyceridemia should be considered. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Testing for mutations in the LDLR, APOB, and PCSK9 genes can be performed in individuals with a clinical diagnosis of <strong>homozygous</strong> FH based on the criteria discussed below [<a href="#rid43">43</a>] (see <a class="local">'Diagnosis'</a> below and <a class="local">'Indications'</a> above). However, in most cases, it does not alter the clinical approach. Genetic testing should be performed in consultation with a lipid specialist and/or geneticist. Genetic testing that does not find a major pathogenic LDL receptor mutation, an ApoB3500 mutation, or a PCSK9 gain-of-function mutations may not necessarily mean that there is no genetic defect. </p><p></p><p class="bulletIndent1">Genetic testing in adults with a clinical picture consistent with <strong>heterozygous</strong> FH does not contribute substantially to clinical decision-making, and its role is not established. </p><p></p><p class="bulletIndent1">The cost for genetic testing may not be reimbursable and some companies test for only a small number of mutations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for lipoprotein(a)</strong> – Patients with FH and an elevated level of lipoprotein(a) have a significantly higher risk of cardiovascular disease events than those with normal lipoprotein(a) levels [<a href="#rid56">56</a>]. Thus, we test for lipoprotein(a) in all patients with FH. The finding of high Lp(a) in someone with elevated LDL-C makes that individual a case of suspected FH and militate in favor of genetic testing [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/4566.html" rel="external">"Lipoprotein(a)", section on 'Genetics'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for apo E variants </strong>– Recently, rare apo E variants have been described that on their own cause FH syndrome. In FH due to LDLR, PCSK9, and APOB3500 mutation, the presence of the more common apo E variant (apoE4) leads to an even higher LDL-C [<a href="#rid58">58</a>].</p><p></p><p class="headingAnchor" id="H3760692422"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of <strong>heterozygous familial hypercholesterolemia (FH)</strong> can be made with genetic testing or clinical criteria. A causative mutation in the LDLR, APOB, or PCSK9 gene(s) secures this diagnosis. (See <a class="local">'Genetic considerations'</a> above.)</p><p>When genetic testing is not available or not felt to be necessary, we use the Dutch Lipid Clinic Network criteria  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 1</a>), which assigns points based on low-density lipoprotein cholesterol (LDL-C) levels, personal history of early atherosclerotic cardiovascular disease (ASCVD), family history of early ASCVD, or high cholesterol in a first-degree relative, and physical examination findings [<a href="#rid43">43</a>]. </p><p>An alternative definition is that of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.heartuk.org.uk%2Fcholesterol%2Ffh-diagnosis-criteria&amp;token=n5XB5ZnhCaTqZQjlqG%2Bhg9awvaZ921n1IvjAumWuaociQ7hPLfc0LP1l8ZiIlEiM8fga6QoZvnZO1tXu7638Qa8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=107507" target="_blank">Simon Broome Register Group</a>, which is used predominately in the United Kingdom [<a href="#rid59">59</a>]. This system classifies patients as having definite or probable heterozygous FH. </p><p>Criteria for the clinical diagnosis of <strong>homozygous FH</strong> include [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Untreated LDL-C &gt;500 mg/dL (&gt;13 mmol/L) or treated LDL-C ≥300 mg/dL (&gt;8 mmol/L), <strong>AND</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous or tendon xanthoma before age 10 years, OR</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated LDL-C levels consistent with heterozygous FH in both parents</p><p></p><p class="bulletIndent2">It is important to note, however, that untreated LDL-C levels &lt;500 do not exclude homozygous FH, particularly in young children. </p><p></p><p class="headingAnchor" id="H1833019618"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>It is important to distinguish FH from other causes of hypercholesterolemia, xanthomata, and/or premature ASCVD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercholesterolemia and premature ASCVD</strong> – Other common causes of hypercholesterolemia and premature ASCVD include  (<a class="graphic graphic_table graphicRef66747" href="/d/graphic/66747.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial combined hyperlipidemia (see  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Familial combined hyperlipidemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperapobetalipoproteinemia (see  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Familial combined hyperlipidemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polygenic hypercholesterolemia (see  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Polygenic hypercholesterolemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) (see  <a class="medical medical_review" href="/d/html/132419.html" rel="external">"Hypertriglyceridemia in adults: Approach to evaluation", section on 'Moderate or moderate to severe hypertriglyceridemia'</a>)</p><p></p><p class="bulletIndent1">The clinical history and evaluation of the lipid profile are helpful in distinguishing these disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xanthomata</strong> – Xanthomata, particularly in children, are highly suggestive of FH, but they can be seen on other rare genetic disorders (eg, sitosterolemia and cerebrotendinous xanthomatosis, described below). In addition, juvenile xanthogranulomas (JXG) and other non-Langerhans cell histiocytoses have a similar appearance and may be mistaken for xanthomata. The distribution of the lesions helps to differentiate xanthomata in FH from the lesions in JXG (in FH, xanthomata commonly occur on Achilles tendons, dorsum of the hands, and extensor surfaces of the knees and elbows; whereas lesions in JXG typically occur on the head, neck, and upper trunk). A definitive distinction is made on the basis of the lipid profile, which is normal in JXG. (See  <a class="medical medical_review" href="/d/html/13729.html" rel="external">"Juvenile xanthogranuloma (JXG)"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tendon xanthomata and premature atherosclerosis</strong> – Tendon xanthomata and premature atherosclerosis can also occur in two rare genetic disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F210250&amp;token=87jLzclRwWxNoI%2BQq5Gg76V7mmZK0n5PcthlVLa09D5nsgSEl6HFm%2F4IYMj0qOOH&amp;TOPIC_ID=107507" target="_blank">Sitosterolemia</a> – Sitosterolemia (alternatively termed "phytosterolemia") is an autosomal recessive disorder associated with hyperabsorption of cholesterol and plant sterols from the intestine [<a href="#rid61">61</a>]. It is characterized by tendinous and/or tuberous xanthomas in childhood associated with very high plasma cholesterol and atherosclerotic complications. Sitosterolemia can be differentiated from FH based upon markedly (&gt;30-fold) increased plasma concentrations of plant sterols. In addition, patients with sitosterolemia typically respond well to diet, <a class="drug drug_general" data-topicid="8790" href="/d/drug information/8790.html" rel="external">ezetimibe</a>, and/or bile acid sequestrants, which generally is not the case in patients with homozygous FH. Diagnosis of sitosterolemia can be confirmed by genetic analysis, with detection of mutations in two ATP-binding cassette transporter (ABC transporters) genes, <em>ABCG5</em>, and/or <em>ABCG8</em> [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F213700&amp;token=87jLzclRwWxNoI%2BQq5Gg70jd%2BGF1VdkFmUwxxw2XKWiaa2fuBpSdd5VQ6aUYEshQ&amp;TOPIC_ID=107507" target="_blank">Cerebrotendinous xanthomatosis</a> – Cerebrotendinous xanthomatosis is caused by a block in bile acid synthesis due to the absence of hepatic mitochondrial 27-hydroxylase (CYP27). It can be distinguished from FH by the presence of neurological, cognitive, and ophthalmic symptoms and usually normal serum cholesterol concentrations. (See  <a class="medical medical_review" href="/d/html/1692.html" rel="external">"Cerebrotendinous xanthomatosis"</a>.)</p><p></p><p class="headingAnchor" id="H2860152380"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>We suggest referring the following groups of patients to a specialist in the care of lipid disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>All those with homozygous familial hypercholesterolemia (FH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All those with heterozygous FH or other primary disorders of low-density lipoprotein cholesterol (LDL-C) metabolism who remain above their LDL-C target on maximum tolerated dose of a statin. (See  <a class="medical medical_review" href="/d/html/111815.html" rel="external">"Familial hypercholesterolemia in adults: Treatment", section on 'Goal of therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2000072320"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prior to the widespread use of statin therapy for patients with heterozygous familial hypercholesterolemia (FH), the risk of premature coronary heart disease (CHD) was very high [<a href="#rid62">62</a>]. In a 1974 study of over 1000 first and second degree relatives of 116 index patients, the risk of fatal or nonfatal CHD by age 60 was 52 percent for male and 32 percent for female relatives [<a href="#rid63">63</a>]. In relatives without FH, the comparable rates were 13 and 9 percent, respectively. Treatment leads to a marked improvement in prognosis. (See  <a class="medical medical_review" href="/d/html/111815.html" rel="external">"Familial hypercholesterolemia in adults: Treatment", section on 'Rationale for intense LDL-C lowering'</a>.)</p><p>At any level of untreated low-density lipoprotein cholesterol (LDL-C), the prognosis for patients with heterozygous FH is worse than those without. Gene (LDLR, APOB, and PCSK9) sequencing (see <a class="local">'Genetic considerations'</a> above) was performed in a study of 1386 patients with LDL-C ≥190 mg/dL [<a href="#rid5">5</a>]. Compared with a reference group with LDL-C &lt;130 mg/dL, those with LDL-C ≥190 mg/dL and an FH mutation had a 22-fold increased risk (odd ratio 22.3, 95% CI 10.7-53.2) for coronary artery disease. </p><p>Some of the heterogeneity in the time course for the development of clinical CHD is likely explained by the presence or absence of other risk factors.</p><p>In heterozygous FH patients who have sustained an acute coronary syndrome and have been treated with high-dose statins, the risk of death and nonfatal myocardial infarction within one year is approximately three times higher than matched individuals without FH [<a href="#rid49">49</a>]. </p><p>For homozygous patients, the extent of reduction of serum cholesterol, achieved by any therapeutic intervention, is a major determinant of survival [<a href="#rid64">64</a>]. </p><p class="headingAnchor" id="H1754853344"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Once we identify familial hypercholesterolemia (FH) in a patient, we strongly recommend screening of all first degree relatives, including children beginning at age two years. This is due to the particularly high risk of premature cardiovascular disease. Screening for and the diagnostic evaluation of FH in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H1453898555"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The primary goal of treatment in patients with familial hypercholesterolemia is reduced the risk adverse cardiovascular disease events by lowering LDL-C. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/111815.html" rel="external">"Familial hypercholesterolemia in adults: Treatment"</a>.)</p><p>Patients in whom the diagnosis of FH has been considered based on a LDL-C ≥190 mg/dL [<a href="#rid5">5</a>], but in whom a monogenic cause has not been established by genetic testing, should not be dismissed as being at lower ASCVD risk, both because certainly in the presence of additional ASCVD risk factors their risk may reach that of monogenic FH and because people with higher LDL-C levels can derive greater benefit from cholesterol-lowering treatment than many with lower levels even in the absence of a monogenic cause.’</p><p class="headingAnchor" id="H1413587606"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111343.html" rel="external">"Society guideline links: Primary prevention of cardiovascular disease"</a> and  <a class="medical medical_society_guidelines" href="/d/html/109532.html" rel="external">"Society guideline links: Lipid disorders in adults"</a>.)</p><p class="headingAnchor" id="H1640308343"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83337.html" rel="external">"Patient education: Familial hypercholesterolemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1557209085"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease caused by functional mutations at one of three genetic loci. In the absence of genetic testing, which confirms one of these mutations, FH is defined based on clinical criteria. (See <a class="local">'Definition'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>– Homozygous patients are rare and have an estimated prevalence of approximately 1:300,000 to 1:400,000. Heterozygous FH is estimated to occur in about 1 in 300 individuals in Europe and 1 in 200 to 250 individuals in the United States. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Previously undiagnosed <strong>heterozygous</strong> FH patients present with symptoms or signs of cardiovascular disease or adverse cardiovascular disease events in early middle age. Many patients will be identified by the finding of a low-density lipoprotein cholesterol (LDL-C) greater than the 90<sup>th</sup> percentile for age and sex when the test was performed for cardiovascular risk screening. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening </strong>– Health care providers should recommend lipid profiles for all first-degree relatives of patients with FH in order to identify other individuals at risk. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– In the absence of aggressive lipid lowering therapy, life span is significantly shortened. In addition, for a given level of LDL-C, the prognosis is worse for FH patients than those without FH. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for referral </strong>– We suggest referring patients with homozygous FH or those with heterozygous FH who do not meet their target LDL-C with statin therapy to a specialist in the care of lipid disorders. (See <a class="local">'Indications for referral'</a> above.)</p><p></p><p class="headingAnchor" id="H4239948970"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Sarah D. de Ferranti for her past contributions as an author to prior versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 2021; 398:1713.</a></li><li><a class="nounderline abstract_t">Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37:1384.</a></li><li><a class="nounderline abstract_t">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1.</a></li><li><a class="nounderline abstract_t">Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560.</a></li><li><a class="nounderline abstract_t">Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 2016; 67:2578.</a></li><li><a class="nounderline abstract_t">Futema M, Shah S, Cooper JA, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231.</a></li><li><a class="nounderline abstract_t">Ajufo E, Cuchel M. Improving the yield of genetic testing in familial hypercholesterolaemia. Eur Heart J 2017; 38:574.</a></li><li><a class="nounderline abstract_t">Shin DG, Han SM, Kim DI, et al. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis 2015; 243:53.</a></li><li><a class="nounderline abstract_t">Clarke RE, Padayachee ST, Preston R, et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013; 99:175.</a></li><li><a class="nounderline abstract_t">Futema M, Whittall RA, Kiley A, et al. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013; 229:161.</a></li><li><a class="nounderline abstract_t">Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407.</a></li><li><a class="nounderline abstract_t">Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S1.</a></li><li><a class="nounderline abstract_t">Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4:850.</a></li><li><a class="nounderline abstract_t">Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943.</a></li><li><a class="nounderline abstract_t">Fouchier SW, Dallinga-Thie GM, Meijers JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 2014; 115:552.</a></li><li><a class="nounderline abstract_t">Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293.</a></li><li><a class="nounderline abstract_t">Wang J, Dron JS, Ban MR, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arterioscler Thromb Vasc Biol 2016; 36:2439.</a></li><li><a class="nounderline abstract_t">Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45:1274.</a></li><li><a class="nounderline abstract_t">Trinder M, Li X, DeCastro ML, et al. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. J Am Coll Cardiol 2019; 74:512.</a></li><li><a class="nounderline abstract_t">Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518:102.</a></li><li><a class="nounderline abstract_t">Tada H, Kawashiri MA, Nohara A, et al. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J 2017; 38:1573.</a></li><li><a class="nounderline abstract_t">Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24:133.</a></li><li><a class="nounderline abstract_t">Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92:883.</a></li><li><a class="nounderline abstract_t">Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148.</a></li><li><a class="nounderline abstract_t">Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915.</a></li><li><a class="nounderline abstract_t">Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009; 155:199.</a></li><li><a class="nounderline abstract_t">Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111:1795.</a></li><li><a class="nounderline abstract_t">Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 Suppl:S172.</a></li><li><a class="nounderline abstract_t">Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res 2008; 49:1152.</a></li><li><a class="nounderline abstract_t">Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30:520.</a></li><li><a class="nounderline abstract_t">Chen SN, Ballantyne CM, Gotto AM Jr, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611.</a></li><li><a class="nounderline abstract_t">Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264.</a></li><li><a class="nounderline abstract_t">Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55:2833.</a></li><li><a class="nounderline abstract_t">Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24:1454.</a></li><li><a class="nounderline abstract_t">Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 2012; 59:1778.</a></li><li><a class="nounderline abstract_t">Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108.</a></li><li><a class="nounderline abstract_t">Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394.</a></li><li><a class="nounderline abstract_t">Defesche JC, Pricker KL, Hayden MR, et al. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153:2349.</a></li><li><a class="nounderline abstract_t">Tybjaerg-Hansen A, Gallagher J, Vincent J, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80:235.</a></li><li><a class="nounderline abstract_t">Tybjaerg-Hansen A, Steffensen R, Meinertz H, et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998; 338:1577.</a></li><li><a class="nounderline abstract_t">Guzauskas GF, Garbett S, Zhou Z, et al. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Ann Intern Med 2023; 176:585.</a></li><li><a class="nounderline abstract_t">de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016; 133:1067.</a></li><li><a class="nounderline abstract_t">Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478.</a></li><li><a class="nounderline abstract_t">Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956.</a></li><li><a class="nounderline abstract_t">Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 1996; 98:479.</a></li><li><a class="nounderline abstract_t">Couture P, Morissette J, Gaudet D, et al. Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Atherosclerosis 1999; 143:145.</a></li><li><a class="nounderline abstract_t">Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation 2020; 141:1742.</a></li><li><a class="nounderline abstract_t">Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol 2020; 75:2553.</a></li><li><a class="nounderline abstract_t">Nanchen D, Gencer B, Muller O, et al. Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. Circulation 2016; 134:698.</a></li><li><a class="nounderline abstract_t">Pang J, Poulter EB, Bell DA, et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol 2015; 9:703.</a></li><li><a class="nounderline abstract_t">Vallejo-Vaz AJ, Ray KK. Epidemiology of familial hypercholesterolaemia: Community and clinical. Atherosclerosis 2018; 277:289.</a></li><li><a class="nounderline abstract_t">Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998; 98:2580.</a></li><li><a class="nounderline abstract_t">Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</a></li><li><a class="nounderline abstract_t">Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425.</a></li><li><a class="nounderline abstract_t">Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J 2015; 36:2438.</a></li><li><a class="nounderline abstract_t">Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63:1982.</a></li><li><a class="nounderline abstract_t">Durrington PN, Bashir B, Bhatnagar D, Soran H. Lipoprotein (a) in familial hypercholesterolaemia. Curr Opin Lipidol 2022; 33:257.</a></li><li><a class="nounderline abstract_t">Marmontel O, Abou-Khalil Y, Bluteau O, et al. Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2023; 43:e270.</a></li><li><a class="nounderline abstract_t">Wierzbicki AS, Humphries SE, Minhas R, Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.</a></li><li><a class="nounderline abstract_t">Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146.</a></li><li><a class="nounderline abstract_t">Gregg RE, Connor WE, Lin DS, Brewer HB Jr. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 1986; 77:1864.</a></li><li><a class="nounderline abstract_t">Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160:421.</a></li><li><a class="nounderline abstract_t">Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49:476.</a></li><li><a class="nounderline abstract_t">Thompson GR, Blom DJ, Marais AD, et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2018; 39:1162.</a></li></ol></div><div id="topicVersionRevision">Topic 107507 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506743" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908947" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222016" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585268" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050191" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25414277" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161618" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Improving the yield of genetic testing in familial hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343872" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23213176" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669246" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15321837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600525" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27246162" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142622" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25035151" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433573" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27765764" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097068" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Discovery and refinement of loci associated with lipid levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345425" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487149" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28159968" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2088165" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8349823" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7584986" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2648148" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19446849" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813012" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020338" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : PCSK9: a convertase that coordinates LDL catabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375913" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : PCSK9 function and physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191301" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15893176" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554528" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579540" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178557" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22575316" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435370" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326085" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215738" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310429" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603795" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37155986" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976914" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23956253" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893714" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8792826" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32468833" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32439005" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27462068" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350818" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30270061" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Epidemiology of familial hypercholesterolaemia: Community and clinical.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843466" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084329" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26009596" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142466" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632281" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35942820" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lipoprotein (a) in familial hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37128917" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753174" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Familial hypercholesterolaemia: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25053660" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711338" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15321838" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Familial hypercholesterolemia and coronary heart disease: a HuGE association review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4813182" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106543" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
